STAT+: Pharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Eli Lilly reported that a high dose of its gene‑editing therapy cut LDL cholesterol by 62% in a Phase 1 trial, with no serious treatment‑related adverse events.
- Eli Lilly acquired the therapy through its $1 billion purchase of Verve Therapeutics last year.
- Eli Lilly plans to launch a Phase 2 study of the cholesterol gene therapy, followed by Phase 3 trials in thousands of patients to seek approval.
- Eli Lilly agreed to purchase three vaccine developers—Curevo, LimmaTech Biologics, and Vaccine Company—in deals worth up to nearly $4 billion, expanding its infectious‑disease portfolio.
Why it matters: Patients with high LDL have a new potential one‑time therapy, and Lilly’s $4 billion vaccine purchases broaden its infectious‑disease pipeline, diversifying its product portfolio beyond GLP‑1 drugs.
